Catheter Precision, Inc. Receives Chinese Patent for LockeT
Catheter Precision, Inc. (VTAK:NYSE/American) has announced the issuance of its first LockeT patent in China. LockeT is a suture retention device used for closing percutaneous catheter access sites during various procedures, including electrophysiology, structural heart, and vascular surgery. The device is currently sold in the US and select international markets.
The company is awaiting CE mark certification, expected in Q1 2025, which will allow access to the European market. CEO David Jenkins highlighted China as a significant market for LockeT, citing its low-cost alternative status and clinical data demonstrating ease of use, patient comfort, and effectiveness in groin management, including early ambulation and same-day discharge.
Catheter Precision, Inc. (VTAK:NYSE/American) ha annunciato il rilascio del suo primo brevetto LockeT in Cina. LockeT è un dispositivo di ritenzione per sutura utilizzato per chiudere i siti di accesso tramite catetere percutaneo durante varie procedure, tra cui elettrofisiologia, chirurgia cardiovascolare e vascolare. Il dispositivo è attualmente venduto negli Stati Uniti e in alcuni mercati internazionali selezionati.
L'azienda sta aspettando la certificazione CE, prevista per il primo trimestre del 2025, che consentirà l'accesso al mercato europeo. Il CEO David Jenkins ha evidenziato la Cina come un mercato significativo per LockeT, citando il suo status di alternativa a basso costo e dati clinici che dimostrano la facilità d'uso, il comfort del paziente e l'efficacia nella gestione dell'inguine, inclusa l'ambulazione precoce e la dimissione lo stesso giorno.
Catheter Precision, Inc. (VTAK:NYSE/American) ha anunciado la emisión de su primera patente LockeT en China. LockeT es un dispositivo de retención de suturas utilizado para cerrar los sitios de acceso a catéteres percutáneos durante varios procedimientos, incluyendo electrofisiología, cirugía cardíaca estructural y vascular. El dispositivo se vende actualmente en los EE. UU. y en algunos mercados internacionales seleccionados.
La empresa está esperando la certificación CE, que se espera en el primer trimestre de 2025, lo que permitirá el acceso al mercado europeo. El CEO David Jenkins destacó a China como un mercado importante para LockeT, citando su estatus de alternativa de bajo costo y datos clínicos que demuestran la facilidad de uso, el confort del paciente y la efectividad en la gestión de la ingle, incluyendo la movilización temprana y el alta el mismo día.
Catheter Precision, Inc. (VTAK:NYSE/American)는 중국에서 첫 번째 LockeT 특허를 발행했다고 발표했습니다. LockeT는 전기생리학, 구조 심장 및 혈관 수술을 포함한 다양한 절차 동안 경피적 카테터 접근 부위를 닫는 데 사용되는 봉합 유지 장치입니다. 이 장치는 현재 미국 및 일부 국제 시장에서 판매되고 있습니다.
회사는 2025년 1분기에 예상되는 CE 마크 인증을 기다리고 있으며, 이는 유럽 시장에 대한 접근을 허용할 것입니다. CEO David Jenkins는 LockeT에 대해 중국이 중요한 시장이라고 강조하며, 저비용 대안으로서의 지위와 사용의 용이성, 환자 편안함, 그리고 사타구니 관리에서의 효과성을 입증하는 임상 데이터를 인용했습니다. 조기 이동과 같은 날 퇴원을 포함합니다.
Catheter Precision, Inc. (VTAK:NYSE/American) a annoncé l'émission de son premier brevet LockeT en Chine. LockeT est un dispositif de rétention de suture utilisé pour fermer les sites d'accès par catheter percutané lors de diverses procédures, y compris l'électrophysiologie, la chirurgie cardiaque structurelle et la chirurgie vasculaire. Le dispositif est actuellement vendu aux États-Unis et sur certains marchés internationaux sélectionnés.
L'entreprise attend la certification CE, prévue pour le premier trimestre 2025, ce qui permettra d'accéder au marché européen. Le PDG David Jenkins a souligné que la Chine représente un marché significatif pour LockeT, évoquant son statut d'alternative à faible coût et des données cliniques démontrant la facilité d'utilisation, le confort du patient et l'efficacité dans la gestion de l'aine, y compris la mobilisation précoce et la sortie le jour même.
Catheter Precision, Inc. (VTAK:NYSE/American) hat die Ausstellung seines ersten LockeT-Patents in China bekannt gegeben. LockeT ist ein Nähtestgerät, das verwendet wird, um die Zugangsstellen für perkutane Katheter während verschiedener Verfahren, einschließlich Elektrophysiologie, strukturelle Herz- und Gefäßchirurgie, zu schließen. Das Gerät wird derzeit in den USA und in ausgewählten internationalen Märkten verkauft.
Das Unternehmen wartet auf die CE-Zertifizierung, die im ersten Quartal 2025 erwartet wird, was den Zugang zum europäischen Markt ermöglichen wird. CEO David Jenkins hob China als einen wichtigen Markt für LockeT hervor und nannte dessen niedrigpreisigen Alternativen sowie klinische Daten, die die Benutzerfreundlichkeit, den Komfort der Patienten und die Effektivität im Leistenmanagement zeigen, einschließlich der frühen Mobilisierung und der Entlassung am selben Tag.
- Received first LockeT patent in China, expanding intellectual property protection
- LockeT is currently sold in the US and select international markets
- CE mark certification expected in Q1 2025, potentially opening up the European market
- Clinical data shows LockeT is easy to apply, comfortable for patients, and effective in groin management
- None.
Insights
The issuance of a Chinese patent for LockeT is a positive development for Catheter Precision, but its immediate impact is While China represents a large potential market, several steps remain before LockeT can be commercialized there:
- Regulatory approval from China's NMPA (National Medical Products Administration) is still required
- A distribution strategy and partnerships need to be established
- Clinical data may need to be generated specifically for the Chinese market
The patent provides intellectual property protection, which is important in the competitive medical device landscape. However, the real value will be realized once LockeT enters the Chinese market, which could take several years.
Investors should note that Catheter Precision is still awaiting CE mark certification for Europe, expected in Q1 2025. This nearer-term milestone could have a more immediate impact on revenues. The company's focus on LockeT as a low-cost alternative in closure devices aligns well with cost-containment efforts in healthcare globally.
The Chinese patent for LockeT expands Catheter Precision's global intellectual property portfolio, which is valuable for a small-cap medical device company (
- Market Size: China's cardiovascular device market is projected to grow significantly, offering long-term potential
- Competition: The "low-cost alternative" positioning could be advantageous in price-sensitive markets
- Regulatory Landscape: Navigating China's regulatory environment can be complex and time-consuming
- Revenue Timeline: Meaningful revenue from China is likely years away
Near-term, investors should focus on the pending CE mark and current sales in the US and select international markets. The Chinese patent is a positive indicator of the company's global strategy but doesn't alter the immediate financial outlook. Catheter Precision's ability to execute in existing markets and secure the CE mark will be more critical for short-term performance.
FORT MILL, SC / ACCESSWIRE / September 24, 2024 / Catheter Precision, Inc. (VTAK:NYSE/American), a company engaged in the development and marketing of technologically advanced products for the cardiac electrophysiology market, today announced that has received notification of the issuance of its first LockeT patent in the country of China.
Locket is a suture retention device used in the closure of percutaneous catheter access sites during any number of catheter procedures including electrophysiology, structural heart, and vascular surgery procedures. Locket is currently sold in the US and select international territories. Catheter Precision is awaiting CE mark certification, expected in the first quarter of 2025, which opens up the large market of European countries.
David Jenkins, CEO of Catheter Precision, commented: "China represents a very large market for LockeT, given that LockeT is a low-cost alternative to other closure devices. Our clinical data demonstrate that LockeT is easy to apply, comfortable to the patient, and works well in the overall groin management of the patient, including early ambulation and same day discharge from the hospital. We are happy to see the Locket intellectual property rights issued in the international markets."
Contact Information
Missiaen Huck
COO
mhuck@catheterprecision.com
9736912000
SOURCE: Catheter Precision, Inc.
View the original press release on accesswire.com
FAQ
What is the significance of Catheter Precision (VTAK) receiving a Chinese patent for LockeT?
When is Catheter Precision (VTAK) expecting to receive CE mark certification for LockeT?
What are the key benefits of Catheter Precision's (VTAK) LockeT device?
In which markets is Catheter Precision's (VTAK) LockeT device currently available?
